University of Virginia and AstraZeneca: ‘Bench to bedside’ partnership in search of novel cardiometabolic therapies
We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical research projects aimed at identifying disease mechanisms and biological targets with potential to become treatments in areas of high unmet medical need.
New appointments for Mene Pangalos reflect AstraZeneca’s ongoing commitment to UK science
Yesterday it was announced that Dr Mene Pangalos, Executive Vice President of our IMED Biotech Unit, has accepted two prestigious appointments reflecting AstraZeneca’s long standing commitment to strengthening UK science.
Cancer Research UK and MedImmune launch ground-breaking biotherapeutics research centre in Cambridge
A new laboratory that will focus on the discovery and development of novel biologic cancer treatments and diagnostics has been opened in Cambridge by life sciences minister George Freeman MP. The state-of-the-art CRUK-MEDI Alliance Laboratory, located on Granta Park, is an innovative collaboration between Cancer Research UK, its commercial arm Cancer Research Technology, and MedImmune, the global biologics research and development arm of AstraZeneca.
Inspirational research showcased at ‘Bridging Bench to Better Medicines’ event in Cambridge
On the 16th September, 2015 more than 100 scientists from AstraZeneca Pharmaceutical Development, MedImmune Biopharmaceutical Development and representatives from academic and commercial research organisations gathered at the Robinson College in Cambridge to discuss science and innovation.
Presenting lupus and gout data at American College of Rheumatology meeting
AstraZeneca, along with MedImmune and Ardea Biosciences, is pleased to be presenting 13 abstracts at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting taking place in San Francisco, California, 6-11 November. The data highlight the progress of our inflammation and autoimmunity pipeline, with a focus on systemic lupus erythematosus (SLE), gout and rheumatoid arthritis, all diseases with serious unmet medical need.
Among the key abstracts being presented are new data on anifrolumab, an investigational therapy for the treatment of SLE, a disease where only one new drug has been approved in over six decades. Anifrolumab blocks the activity of all Type I interferons, which could offer a new approach to treating lupus.
We’re also presenting data for lesinurad for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor.
For more information, follow us on Twitter @AstraZeneca @MedImmune
Image: Artistic rendering of an antibody in inflammation and autoimmunity.
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
The best science doesn't happen in isolation.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 929087.011
Date of next review: November 2016